Physician profile
Richard E Berman
NPI 1427065390
$458.13
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $119.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $182.95 | 2019-2020 | |
| Janssen Biotech, INC. | $72.54 | 2019 | |
| Ferring Pharmaceuticals INC. | $60.96 | 2019-2020 | |
| Pfizer INC. | $30.26 | 2019 | |
| Merck Sharp & Dohme LLC | $28.25 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.71 | 2020 | |
| Daiichi Sankyo INC. | $17.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.01 | 2019 | |
| Gilead Sciences, INC. | $13.46 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.66 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.